Less Visibility On Long-Term Earnings Turn Investors Cautious On Indian Pharma; Government’s Apathy Adds To Concerns
This article was originally published in PharmAsia News
Executive Summary
Singapore- and Hong Kong-based senior analysts, portfolio and hedge fund managers interviewed by PharmAsia News said the Indian market is undergoing a transition phase and shows limited upsides.